Literature DB >> 1742648

Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance.

C Lunardi1, L M Bambara, D Biasi, P Cortina, P Peroli, F Nicolis, F Favari, M L Pacor.   

Abstract

Twenty patients with irritable bowel syndrome due to food intolerance were randomized to either oral sodium cromoglycate or placebo in a double-blind cross-over trial. The study consisted of treatment with either sodium cromoglycate or placebo for 8 weeks, followed by the cross-over treatment for 8 further weeks. Patients were allowed to eat the offending foods during the study. Eighteen patients completed the study. Analysis of patients' diary card scores showed a statistically significant difference in favour of sodium cromoglycate. There was a long carry-over effect in the active-placebo order group. Therefore oral sodium cromoglycate seems to be a useful treatment in patients with irritable bowel syndrome and proven food intolerance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742648     DOI: 10.1111/j.1365-2222.1991.tb00848.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  15 in total

1.  Mast cells and intestinal motility disorders (mastocytic enteritis/colitis).

Authors:  David F Schaeffer; Richard Kirsch; Robert H Riddell
Journal:  Dig Dis Sci       Date:  2012-05       Impact factor: 3.199

Review 2.  Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia.

Authors:  Craig A Friesen; Jennifer V Schurman; Jennifer M Colombo; Susan M Abdel-Rahman
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-11-06

Review 3.  Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity.

Authors:  Pasquale Mansueto; Alberto D'Alcamo; Aurelio Seidita; Antonio Carroccio
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

Review 4.  Treatment of irritable bowel syndrome: a review of randomised controlled trials.

Authors:  R Akehurst; E Kaltenthaler
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 5.  Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome.

Authors:  Pejman Katiraei; Gilberto Bultron
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 6.  The mucosal immune system: master regulator of bidirectional gut-brain communications.

Authors:  Nick Powell; Marjorie M Walker; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-18       Impact factor: 46.802

Review 7.  Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome.

Authors:  Yehuda Ringel; Nitsan Maharshak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-07-25       Impact factor: 4.052

8.  Risk factors for chronic diarrhoea in the community in the absence of irritable bowel syndrome.

Authors:  J Y Chang; G Richard Locke; C D Schleck; A R Zinsmeister; N J Talley
Journal:  Neurogastroenterol Motil       Date:  2009-05-21       Impact factor: 3.598

Review 9.  Update on the Role of Allergy in Pediatric Functional Abdominal Pain Disorders: A Clinical Perspective.

Authors:  Craig Friesen; Jennifer Colombo; Jennifer Schurman
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

Review 10.  Guidelines on the irritable bowel syndrome: mechanisms and practical management.

Authors:  R Spiller; Q Aziz; F Creed; A Emmanuel; L Houghton; P Hungin; R Jones; D Kumar; G Rubin; N Trudgill; P Whorwell
Journal:  Gut       Date:  2007-05-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.